HHS Rebate Rule: At Least We Know Who Is In Charge
Executive Summary
HHS proposal to eliminate the “safe harbor” that allows for prescription drug rebates took a long time to clear White House review. Its release sends a clear message that US HHS Secretary Azar wants to lead the drug pricing debate in 2019.
You may also be interested in...
Capping Off The Rebate Debate: Will 2019 Price Push End With Co-Pay Cap?
The pharmaceutical industry and its strongest critics have long agreed on one thing: Medicare Part D would be improved if there was a cap on spending by beneficiaries. Now, there is an unlikely path that may make it surprisingly easy to get it done.
HHS Rebate Reform: An Air Of Inevitability In Stakeholder Comments
Manufacturers, pharmacy benefit managers and insurers weigh in on the Trump administration’s most significant drug pricing action to date – the HHS Office of Inspector General's proposed rule aimed at eliminating rebates.
CMS Offers Part D Plans Financial Backstop If Rebates Eliminated In 2020
But CMS also advises Medicare Part D plans to develop bids for the 2020 plan year that include rebates, since the final version of the HHS rule eliminating the anti-kickback safe harbor for rebates may not be released in time for the June 3 bid submission deadline.